These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 1481056

  • 1. [Reflex oximetry for evaluating blood redistribution in patients with arterial occlusive disease treated with PGE1].
    Thum J, Caspary L, Creutzig A, Alexander K.
    Vasa Suppl; 1992; 35():39-41. PubMed ID: 1481056
    [No Abstract] [Full Text] [Related]

  • 2. Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease.
    Thum J, Caspary L, Creutzig A, Alexander K.
    Vasa; 1998 May; 27(2):100-5. PubMed ID: 9612114
    [Abstract] [Full Text] [Related]

  • 3. [Double-blind placebo-controlled study of the behavior of tcPO2 during intravenous infusion of prostaglandin E1 in patients with severe arterial occlusive disease].
    Creutzig A, Caspary L, Alexander K.
    Vasa Suppl; 1992 May; 35():36-8. PubMed ID: 1481055
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].
    Weiss T, Griesshaber J, Rogatti W, Kistner O, Hsu E, Jansen T, Diehm C.
    Vasa Suppl; 1991 May; 33():341-2. PubMed ID: 1788749
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].
    Fitscha P, Simmet T, Peskar BA, Reuter H, Sinzinger H, Rogatti W, Tilsner V.
    Wien Klin Wochenschr; 1988 Jul 15; 100(14):477-81. PubMed ID: 3062905
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].
    Weiss T.
    Vasa; 2003 Nov 15; 32(4):187-92. PubMed ID: 14694766
    [Abstract] [Full Text] [Related]

  • 16. Effects of intravenous and intra-arterial infusions of prostaglandin E1 on canine hindlimb blood flow distribution.
    Lynch TG, Hobson RW, Barbalinardo JP, Kerr JC.
    Surgery; 1984 Jul 15; 96(1):35-41. PubMed ID: 6539953
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Administration of prostaglandin E1 in diabetics and non-diabetic patients with severe Fontaine stage IIb arterial occlusive disease].
    Hinderer S, Brachmann R, Nedder KH, Bucher J, Beischer W.
    Vasa; 1991 Jul 15; 20(2):100-8. PubMed ID: 1877328
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.